Climb Bio Inc
CLYM
View Detailed Chart
4.900USD
+0.620+14.49%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
334.10MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+14.49%
5 Days
+28.61%
1 Month
+188.24%
6 Months
+304.96%
Year to Date
+172.22%
1 Year
+151.28%
View Detailed Chart
TradingKey Stock Score of Climb Bio Inc
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered undervalued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Climb Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
9.200
Target Price
+408.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Climb Bio Inc Highlights
StrengthsRisks
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -111.94, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.41M shares, decreasing 14.31% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 2.54K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.60.
Climb Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Climb Bio Inc Info
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Ticker SymbolCLYM
CompanyClimb Bio Inc
CEOBrennan (Aoife M)
Websitehttps://climbbio.com/
FAQs
What is the current price of Climb Bio Inc (CLYM)?
The current price of Climb Bio Inc (CLYM) is 4.900.
What is the symbol of Climb Bio Inc?
The ticker symbol of Climb Bio Inc is CLYM.
What is the 52-week high of Climb Bio Inc?
The 52-week high of Climb Bio Inc is 4.820.
What is the 52-week low of Climb Bio Inc?
The 52-week low of Climb Bio Inc is 1.050.
What is the market capitalization of Climb Bio Inc?
The market capitalization of Climb Bio Inc is 334.10M.
What is the net income of Climb Bio Inc?
The net income of Climb Bio Inc is -73.90M.
Is Climb Bio Inc (CLYM) currently rated as Buy, Hold, or Sell?
According to analysts, Climb Bio Inc (CLYM) has an overall rating of --, with a price target of 9.200.
What is the Earnings Per Share (EPS TTM) of Climb Bio Inc (CLYM)?
The Earnings Per Share (EPS TTM) of Climb Bio Inc (CLYM) is -0.592.
Related Instruments
+0.44%
+0.43%
+0.45%
+0.21%
+0.60%
+3.60%
+1.22%
+0.04%
-0.10%
+0.10%
-0.31%
+0.90%
+0.82%
-0.25%
-0.02%
+0.71%
+1.48%
0.00%
+1.25%
+1.87%Popular Symbols
